Ocugen (OCGN) Competitors

Immatics (NASDAQ:IMTX) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

Do insiders & institutionals have more ownership in IMTX or OCGN?

64.4% of Immatics shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Comparatively, 4.3% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Is IMTX or OCGN more profitable?

Immatics has a net margin of -47.94% compared to Ocugen's net margin of -532.51%. Immatics' return on equity of -15.90% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-47.94%	-15.90%	-9.38%
Ocugen	-532.51%	-154.75%	-90.79%

Does the media prefer IMTX or OCGN?

In the previous week, Immatics had 3 more articles in the media than Ocugen. MarketBeat recorded 5 mentions for Immatics and 2 mentions for Ocugen. Immatics' average media sentiment score of 1.01 beat Ocugen's score of 0.44 indicating that Immatics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocugen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer IMTX or OCGN?

Ocugen received 77 more outperform votes than Immatics when rated by MarketBeat users. However, 75.00% of users gave Immatics an outperform vote while only 69.93% of users gave Ocugen an outperform vote.

Company	Underperform	Outperform
Immatics	Outperform Votes 30 75.00%	Underperform Votes 10 25.00%
Ocugen	Outperform Votes 107 69.93%	Underperform Votes 46 30.07%

Which has more risk & volatility, IMTX or OCGN?

Immatics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.82, indicating that its share price is 282% more volatile than the S&P 500.

Do analysts recommend IMTX or OCGN?

Immatics presently has a consensus price target of $16.67, indicating a potential upside of 117.01%. Ocugen has a consensus price target of $5.67, indicating a potential upside of 552.62%. Given Ocugen's higher possible upside, analysts plainly believe Ocugen is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
Ocugen	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better valuation and earnings, IMTX or OCGN?

Ocugen has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$115.50M	7.94	-$104.98M	-$0.66	-11.64
Ocugen	$6.04M	41.88	-$63.08M	-$0.18	-4.82

Summary

Immatics beats Ocugen on 11 of the 19 factors compared between the two stocks.